PMID- 18288397
OWN - NLM
STAT- MEDLINE
DCOM- 20080520
LR  - 20211203
IS  - 1021-335X (Print)
IS  - 1021-335X (Linking)
VI  - 19
IP  - 3
DP  - 2008 Mar
TI  - Prognostic utility of fluorescence in situ hybridization for determining HER2 
      gene amplification in breast cancer.
PG  - 651-6
AB  - An accurate investigation of the HER2 proto-oncogene is extremely important for 
      the therapy and prognostication of breast cancer. Currently, immunohistochemistry 
      (IHC) and fluorescence in situ hybridization (FISH) are standard methods for this 
      purpose. The aim of this study was to detect the expression and amplification of 
      HER2 in paraffin-embedded samples of breast cancer tissue and to investigate the 
      relationship between HER2 amplification and various clinicopathological 
      parameters in advanced breast cancers. We used FISH to examine the HER2 gene 
      amplification and IHC to examine the expression of HER2 protein, estrogen 
      receptor (ER) and progesterone receptor (PR) in 62 advanced breast cancers. HER2 
      gene amplification was detected by FISH in 12 breast cancers (19%) and HER2 
      protein expression with a score of 3+ was detected by IHC in 11 (17%). There was 
      a significant correlation between the HER2 gene amplification and HER2 protein 
      overexpression in breast cancers (P<0.0001). However, some mismatching was 
      evident: 3 cases, negative for the HER2 gene, showed a HER2 protein expression 
      score of 3+ and 2 cases, positive for HER2 gene amplification, had HER2 protein 
      expression scores of 0 and 1+ (negative), respectively. ER and PR were expressed 
      in 41 (66%) and 46 (74%) cancers, respectively. No correlation was observed 
      between the HER2 gene amplification and any of the clinicopathological parameters 
      examined, including age, histopathological type, TNM stage, tumor size, lymph 
      node status, relapse and expression of PR. We observed three patterns among the 6 
      deceased cases: i) triple negativity for HER2, ER and PR, ii) positivity for HER2 
      gene amplification with a mismatching HER2 protein expression, and iii) 
      positivity for the HER2 gene amplification with a matching HER2 protein 
      expression score of 2+ or 3+. The triple negative cases and HER2 gene 
      amplification positive cases with a mismatching HER2 protein expression had a 
      poor outcome. These results suggest that in breast cancer, the detection of HER2 
      gene amplification by FISH is desirable compared with the HER2 protein expression 
      determined by IHC. Moreover, triple negativity for HER2, ER and PR is a 
      potentially very important prognostic marker.
FAU - Kammori, Makoto
AU  - Kammori M
AD  - Department of Surgery, Kanaji Thyroid Hospital, Tokyo 114-0015, Japan. 
      kanmori-dis@umin.ac.jp
FAU - Kurabayashi, Rie
AU  - Kurabayashi R
FAU - Kashio, Mitsuhiko
AU  - Kashio M
FAU - Sakamoto, Akiko
AU  - Sakamoto A
FAU - Yoshimoto, Masataka
AU  - Yoshimoto M
FAU - Amano, Sadao
AU  - Amano S
FAU - Kaminishi, Michio
AU  - Kaminishi M
FAU - Yamada, Tetsu
AU  - Yamada T
FAU - Takubo, Kaiyo
AU  - Takubo K
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PL  - Greece
TA  - Oncol Rep
JT  - Oncology reports
JID - 9422756
RN  - 0 (MAS1 protein, human)
RN  - 0 (Proto-Oncogene Mas)
RN  - 0 (Receptors, Estrogen)
RN  - 0 (Receptors, Progesterone)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Breast Neoplasms/*diagnosis/pathology
MH  - Female
MH  - *Gene Amplification
MH  - *Genes, erbB-2
MH  - Humans
MH  - Immunohistochemistry
MH  - *In Situ Hybridization, Fluorescence
MH  - Middle Aged
MH  - Prognosis
MH  - Proto-Oncogene Mas
MH  - Receptor, ErbB-2/metabolism
MH  - Receptors, Estrogen/metabolism
MH  - Receptors, Progesterone/metabolism
EDAT- 2008/02/22 09:00
MHDA- 2008/05/21 09:00
CRDT- 2008/02/22 09:00
PHST- 2008/02/22 09:00 [pubmed]
PHST- 2008/05/21 09:00 [medline]
PHST- 2008/02/22 09:00 [entrez]
PST - ppublish
SO  - Oncol Rep. 2008 Mar;19(3):651-6.